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Donors after cardiac death (DCD) could increase the
organ pool. Data supports good long-term renal graft
survival. However, DCDs are <10% of deceased donors
in the United States, due to delayed graft function, and
primary nonfunction. These complications are mini-
mized by extracorporeal support after cardiac death
(ECS-DCD). This study assesses immediate and acute
renal function from different donor types. DCDs kid-
neys were recovered by conventional rapid recovery or
by ECS, and transplanted into nephrectomized healthy
swine. Warm ischemia of 10 and 30 min were evalu-
ated. Swine living donors were controls (LVD). ECS-
DCDs were treated with 90 min of perfusion until or-
gan recovery. After procurement, kidneys were cold
storage 4–6 h. Renal vascular resistance (RVR), urine
output (UO), urine protein concentration (UrPr) and
creatinine clearance (CrCl), were collected during 4 h
posttransplantation. All grafts functioned with ade-
quate renal blood flow for 4 h. RVR at 4 h post-
transplant returned to baseline only in the LVD group
(0.36 mmHg/mL/min ± 0.03). RVR was higher in
all DCDs (0.66 mmHg/mL/min ± 0.13), without dif-
ferences between them. UO was >50 mL/h in all
DCDs, except in DCD-30 (6.8 mL/h ± 1.7). DCD-30
had lower CrCl (0.9 mL/min ± 0.2) and higher UrPr
>200 mg/dL, compared to other DCDs >10 mL/min
and <160 mg/dL, respectively. Normothermic ECS
can resuscitate kidneys to transplantable status after
30 min of cardiac arrest/WI.
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Extracorporeal Support Improves Donor
Renal Graft Function After Cardiac Death
End-stage renal disease is treated successfully with kidney
transplantation; however, this therapeutic option is limited
due the shortage of organs available for transplantation.
The waiting list for kidney transplants in the United States
reached more than 82 500 patients in 2008, despite a 30%
increase in the number of renal transplants performed in
2007 (16 628) compared to 10 years ago (11 703). In 2007, a
vast majority of transplanted renal grafts were from donors
after neurologic determination of death (DND), or brain
dead donors, with a significant portion (6041) from living
donors (1).
The use of organs recovered from donors following circu-
latory determination of death (DCD)—previously known as
non-heart beating donors—has the potential to increase
the donor pool; but currently accounts for less than 8% of
all organ transplants (2). The reason is that organs taken
by ‘rapid recovery’ from DCD donors do not function as
well as organs from DND, especially initially. Poor imme-
diate graft function can be tolerated for renal transplants
because of renal replacement therapies like dialysis, so al-
most all organs from DCD are kidneys. The incidence of
delayed graft function and primary graft nonfunction for
kidneys from DCD is significantly higher than kidneys from
DND, in some series more than double (3,4). This is pre-
sumed to be due to the warm ischemic and hypoxic injury
that inevitably occurs following withdrawal of life support
until the organs are cold perfused.
The use of normothermic venoarterial extracorporeal mem-
brane oxygenation support (hereafter called ECS) after car-
diac arrest restores circulation of warm oxygenated blood
to the abdominal organs. It can be initiated immediately
following declaration of death. Experimental data from our
lab has shown that kidney and liver function returns and
is maintained while on ECS (5). In animals, perfusing with
warm oxygenated blood has been shown experimentally
to increase the energy charge (ADP) and antioxidant levels
in the recovered organs (6,7). By restarting circulation after
cardiac arrest, the agonal, hypoxic and ischemic events
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surrounding death and subsequent reperfusion can be
turned into an ischemic preconditioning phenomenon (8).
In our clinical experience the donor pool was expanded
by 33% by establishing normothermic, oxygenated blood
perfusion of abdominal organs using ECS shortly after cir-
culatory determination of death. Moreover it allowed for
controlled, unhurried organ procurement; delayed graft
function was developed in only two grafts (8%) (9).
The use of DCD grafts is encouraged in all the US trans-
plant programs, but there is hesitation among clinical per-
sonnel due to uncertainty about the immediate and long-
term outcomes of these grafts, especially when the organs
come from DCD donors that also fit criteria for expanded
criteria donors (ECD). These donors are over 60 years of
age or over 50 years of age with a history of hyperten-
sion, poor renal function at the time of recovery, or death
due to cerebrovascular accident. While ECS–DCD offers
potentially improved results, it is also perceived as costly.
However, if ECS–DCD can improve initial graft function, the
cost of ECS is offset by the reduced hospital stay and need
for dialysis if the kidneys function immediately. We devel-
oped an animal study to assess the immediate renal graft
function from DCD donors under various warm ischemia
times. This study was designed to evaluate ECS compared
to rapid recovery in a swine model of renal transplantation
after DCD.
Material and Methods
This study was approved by the University of Michigan University Com-
mittee on Use and Care of Animals (UCUCA). All pigs received humane in
compliance with the Guide for the Care and Use of Laboratory Animals.
Experimental design
Using a standard swine model of cardiac death and warm ischemia, kidneys
were removed by conventional rapid recovery or ECS, stored for 4–5 h
cold ischemia, transplanted into nephrectomized swine recipients. Warm
ischemia times of 10 and 30 min were compared. Kidneys transplanted
from living donors (LVD) served as a control group. Five groups of 5 animals
each were compared as shown in Table 1.
Animal model
The following model was used in all experiments. Female swine (weigh-
ing 25–30 kg), were sedated with an intramuscular (i.m) mix of 5 mg/kg
Tiletamine HCl and Zolepam HCl (Telazol, Wyeth Holdings Corporation; Car-
olina, Puerto Rico) and 3 mg/kg Xylazine (TranquiVed Vedco, St. Joseph,
MO). Swine were intubated and mechanically ventilated (MV) with 100%
O2 and 1–3% Isofluorane (Hospira, Lake Forest, IL). Initial MV settings
were adjusted to maintain pCO2 between 35–45 mmHg, and peak inspi-
ratory pressures <25 cmH2O. The right carotid artery and right internal
jugular vein were catheterized to monitor arterial blood pressure and heart
rate and to collect blood samples. A CCOmbo-CCO/SvO2/VIP pulmonary
artery catheter (Edwards Lifesciences, Irvine, CA) was placed via the inter-
nal jugular vein for administration of fluids and monitoring of cardiac output
and central venous pressure. At the end of surgical instrumentation and
prior to baseline data collection, a 20 min acclimation period was allowed
for all animals.
Donor models
1. LVD model: 100 U/kg Heparin Sodium (APP Pharmaceuticals;
Schaumburg, IL) was administered 5 min before proximal ligation of
the renal artery. The kidneys were subsequently resected, flushed with
300–500 mL of Custodiol (Methapharm Inc, Brantford, ON, Canada), and
stored cold for 4–5 h before transplantation.
2. DCD model: Anesthetized pigs were paralyzed using Pancuronium Bro-
mide (Hospira) and cardiac death was achieved by apnea. The agonal
period was 17 ± 1.8 min, simulating at some extent the clinical real-
ity. Circulatory death was defined as: asystole or pulse-less arrhythmia
with a pulse pressure less than 15 mmHg. After death, warm ischemia
(WI)/asystole times of 10 and 30 min were examined. These times are
two and six times longer than the 5 min period that is frequently used
in the United States as a ‘no touch’ period. To achieve anticoagulation,
heparin (100 U/kg) was administered 1min after withdrawal of respi-
ratory support. Kidneys were then recovered in one of the following
ways.
a. Rapid recovery/Conventional: After death, a midline laparotomy was
performed to obtain access to the kidneys. The vessels were identi-
fied and surrounding soft tissue was dissected. After a period of 10
or 30 min of warm ischemia, the pig was cooled via ice in the abdom-
inal cavity, followed by rapid removal of the renal grafts. Grafts were
managed as in the LVD protocol with immediate cold perfusion and
storage.
b. ECS procurement: After death, both external jugular veins were can-
nulated with two 20–23 Fr venous cannulae (to obtain access to the
RA), and a 14–16 Fr arterial cannula was advanced into the abdominal
aorta via right iliac or femoral artery. The V-A ECS circuit animal model
is represented in Figure 1, include: a roller pump (Cobe Cardiovas-
cular, Lakewood, CO), an external heat-exchanger (Seabrook Medical
System, Cincinnati, OH), and a membrane oxygenator (Affinity, NT,
Medtronic; Minneapolis, MN; Rochester, NY) and then stepped up to
3/8” tubing to connect them to the oxygenator outlet. Pump flows
were continuously monitored using a T208 monitor (Transonic Sys-
tem, Ithaca, NY). The membrane oxygenator was primed with saline
and 50 mEq of HCO3 and maintained at 38◦C. After 10 or 30 min of WI
venoarterial perfusion was begun and maintained at 50 cc/kg/min for
90–100 min, aiming to maintain a CVP between 7–16 cmH2O during
Table 1: Donor type and characteristics
Warm Procurement Cold
Donor type Group name ischemia technique ischemia (n)
Living donor LVD <1 min Standard 4–5 h 5
DCD DCD l0 min 10 min Rapid raceway 4–5 h 5
DCD30 min 30 min Rapid leeway 4–5 h 5
ECS-DCD ECS-DCD l0 min 10 min 90 min ECS 4–5 h 5
ECS-DCD 30 min 30 min 90 min ECS 4–5 h 5
LVD = living donors; DCD = donors after cardiac death; ECMO = extracorporeal membrane oxygenation.
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Figure 1: ECS-DCD laboratory
model.
ECS, avoiding cavitation or hemodilution (targeting hematocrit value
>23%). The kidneys were removed while warm perfusion continued,
and managed as in the LVD protocol with immediate cold perfusion
and similar storage time.
Recipient model
Healthy swine underwent surgical instrumentation as described above plus
bilateral nephrectomies. After removal of one kidney, a perivascular renal
(Transonic System, Ithaca, NY) flow probe was placed to obtain measure-
ment of normal renal blood flow to the contralateral kidney for baseline. A
blood sample was collected, and urine output was quantified and collected
for determination of creatinine and protein concentration. The donor kidney
was implanted and the remaining kidney was removed. The inferior vena
cava and infrarenal abdominal aorta were prepared for side-to-end vascu-
lar anastomosis of the experimental renal graft. Heparin (100 U/kg) and
125 mg of methylprednisolone (Solumedrol, Pharmacia & Upjohn, New
York, NY) were administered 5 min before surgical anastomosis. A catheter
was advanced in the ureter for urine output collection. The pig remained
under anesthesia for the entire experiment. For all recipients, maintenance
i.v fluid was 120–150 mL/h, plus 1:1 replacement of urine output with NSS,
maintaining CVP between 12 ± 3 cmH2O.
Data acquisition
Data collected during the experiment are summarized in Table 2. Base-
line (BL) data were collected on the single recipient kidney after surgical
instrumentation but before implantation of renal grafts.
Data analysis
Renal vascular resistance (RVR) was calculated using the following equa-
tion: RVR = (MAP-CVP)/RAF. Creatinine clearance (mL/min) was calculated
using the following equation: CrCl = ([U] × (UO/60))/[P], in which [U] =
urine concentration of creatinine, [P] = plasma concentration of creatinine,
and UO = urine output in mL/h. Urine was collected continuously from
the ureter, during the total length of the study (4 h). This measurement
is not affected by serum concentration of creatinine because it did not
change significantly during the collection period. A mixed model analysis
was performed within SPSS 17.0 (Chicago, IL) to examine the effect of
procurement technique on all acquired data. The pig/experiment number
is the repeated measure variable, and the independent variables were the
experimental group, and the experimental time. The dependant variables
were recipient hemodynamics (MAP, CVP), renal hemodynamics (flows, re-
sistance), UO, CrCl and urine protein concentration. Last, post hoc analysis
using a Bonferroni-corrected confidence interval was used to determine
Table 2: Data acquisition
Variable Type Frequency Description
Renal Recorded every 30 min MAP: mean arterial pressure; CVP: central venous
Hemodynamics after transplantation pressure; RAF: renal artery flow; RVR: renal vascular
resistance
Renal function Baseline and every 1h Urine output (UQ); urine protein
after transplantation concentration (UrPr)
Venous & arterial Baseline, end of CA, every Blood pH; pCO2 pO2; hemoglobin;
Blood gases 1h after transplantation hematocrit; oxyhemoglobin saturation; electrolytes (Na, K,
Ca, Cl and HCO3)∗∗
Chemistry panel Baseline; immediately Plasma creatinine; BUN and ADL; urine
after reperfusion, and 4 h after
traınsplantation.
creatinine; BUN and protein. ∗∗∗
∗BIOPAC Systems, Goleta, CA; ∗∗Radiometer A/S, Copenhagen NV Denmark; ∗∗∗Animal Diagonostic Lab of the University of Michigan.
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Table 3: Graft cold ischemia time and DCD-ECS run characteristic
Average graft cold ischemia time per donor group in minutes
LVD DCD l0 min DCD 30 min ECS-DCD 10 min ECS-DCD 30 min
288.7 ± 11.8 266.0 ± 18.9 262.6 ± 11.9 263.0 ± 11.9 265.8 ± 10.7
DCD-ESC run characteristics (n = 3)
ECS-DCD group Baseline 30 min ECS 60 min ECS 90 min ECS
MAP (mmHg) 10 min 67.3 ± 5.7 48.3 ± 6.2 70.3 ± 13.6 76.3 ± 9.9
30 min 76.3 ± 5.0 41.6 ± 8.4 46.0 ± 7.5 51.0 ± 10.6
ECS flows (L/min) 10 min N/A 1.6 ± 0.5 1.6 ± 0.5 1.7 ± 0.4
30 min N/A 1.6 ± 0.1 1.75 ± 0.01 1.7 ± 0.2
CVP (cmH2O) 10 min 13.0 ± 1.8 12.7 ± 2.8 9.2 ± 3.6 9.1 ± 3.3
30 min 10.4 ± 0.5 10.1 ± +4.4 11.1 ± 3.2 8.3 ± 2.0
Hematocrit % 10 min 31.6 ± 1.5 28.4 ± 2.0 32.4 ± 1.8 34.8 ± 3.3
30 min 33.8 ± 0.6 30.1 ± 0.6 24.6 ± 1.5 28.4 ± 2.2
differences between experimental groups. Values of p < 0.05 were con-
sidered statistically significant. Results are expressed as mean values with
errors bars representing standard error. At the end of the study, the entire
kidney was removed for histopathology; two, 2 cm × 2 cm tissue samples
were placed in formalin. The histoslides were processed by the University
of Michigan Unit for Laboratory Animal Medicine, and read by a blinded
pathologist.
Results
All grafts were successfully transplanted into each healthy
but nephrectomized swine recipient. Average cold storage
times per group and ECS-DCD perfusion characteristics
are summarized in Table 3.
Recipients systemic hemodynamics
In all experimental groups, mean arterial pressure (MAP)
was kept between 60–90 mmHg as shown in Figure 2;
and CVP was maintained between 12 ± 3 cmH2O during
the whole experimental time in all groups. In most cases,
MAP was maintained at baseline levels. However, MAP
decreased significantly (p < 0.05) immediately after reper-
fusion in the DCD 30 min group. This decrease in MAP
resolved after approximately 5 min of reperfusion and re-
turned to baseline values by the 30 min data point. After
this point there were not significant differences between
groups.
Renal hemodynamics and function
Renal artery flow (RAF) following transplantation was
higher at the end of the experiment in the group that re-
ceived grafts from LVD (p < 0.05) compared to all DCD
groups (Figure 3). RAF was lower only in the DCD-10 min
group through all the experimental time, compared to other
DCD groups.
As expected renal vascular resistance (RVR) Figure 4, cor-
related with RAF. It increased significantly immediately af-
ter reperfusion in all groups due to cold preservation, and
returned to normal only in the LVD group (p < 0.05). In the
other four groups, RVR was slightly higher than normal,
baseline values during the whole experiment, without sig-
nificant differences between them.
Figure 2: Recipients mean artial
pressure (MAP). Error Bars = SEM/
(n = 5).
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Figure 3: Recipients renal artery
blood flow (RAF). Error Bars =
SEM/(n = 5).
Urine Output is represented in Figure 5. Although all
groups had some urine output, the amount produced in
the DCD-30 min group was minimal (6.8 ± 1.7 mL/h), and
significantly less than in the other groups that all had urine
output of more than 50 mL/h by the fourth hour.
Creatinine Clearance (CrCl) is represented in Figure 6: CrCl
was significantly lower (p < 0.05) in the DCD-30 group
0.9 ± 0.2 mL/min, compared to the other groups after 1-h
posttransplant. Only grafts from the LVD group returned
back to normal values (∼25 mL/min) after 4 h of reperfu-
sion. The DCD-30 min group had significantly lower CrCl at
1 and 4-h posttransplantation, compared to all the groups.
In particular, when ECS support was used, after 30 min
of warm ischemia (ECS-DCD 30 min), the CrCl was sim-
ilar to those DCD that sustained only 10 min of warm
ischemia.
Urine protein concentration (UrPr) at 1 and 4 h following
reperfusion is represented in Figure 7. UrPr was significant
higher (p < 0.05) in the DCD 30-min group compared to all
other groups where normal values for healthy swine of this
size were evident at the end of the experimental time.
Renal pathology
A summary of the pathologic findings from renal tissue
collected at the end of the experiment can be found in
Table 4. Grafts from DCD 30 min shown some signs of
reversible acute tubular necrosis. No infarcts were seen.
Discussion
The increasing gap between organ demand and organ
sources has led the medical community to go back to the
Figure 4: Calculated renal vascu-
lar resistance (RVR). Error Bars =
SEM/(n = 5).
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Figure 5: Recipients urine output
(UO). Error Bars = SEM/(n = 5).
way that grafts were procured in the early days of trans-
plantation through the use of grafts from DCD. However
renal grafts from DCD are associated with higher rates of
delayed-graft function, primary graft-non-function and, in
some series, long-term graft survival (10–12).
After procurement with conventional techniques (rapid re-
covery) renal grafts had different outcomes directly related
to the extent of warm ischemia time. In 1995, Chang et
al. (13), reported 26% of PGNF (excluding rejection) when
organs from nonheart beating donors (NHBD) were used.
More recently the rates of PGNF in renal grafts are: LVD
2%, brain dead/heart beating donors 3%, and NHBD 7%.
The rate of DGF after rapid recovery is 40–50%. The rates
of DGF in kidneys from heart-beating donors is 25–30%,
significant lower compared to DCD organs. (4,11,14,15)
Despite higher rates of DGF reported when kidneys from
DCD are used the long-term survival rates some reports
show graft survival that is similar to heart-beating donors
at 2, 4 and 6 years (16–24).
Due to the poor outcomes when DCD grafts were used,
ex-vivo perfusion with a cold acellular solution is often used
to measure renal vascular resistance in the donor kidney.
This method allows transplant centers to identify grafts
with elevated resistance and these kidneys were simply
discarded. When implemented, the rates of PGNF were
reduced to as little as 5% (25). The use of this technique
became standard in many DCD programs (26–28).
Hypothermic extracorporeal support has been used in as-
sociation with rapid recovery. Koyoma et al. used cardiopul-
monary bypass at 18◦C and reported high rate of DGF in
kidneys subjected to long periods of warm ischemia (29
Figure 6: Recipients measurement
of CrCl. Error Bars = SEM/(n = 5).
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Figure 7: Recipients urineprotein
concentration (UrPr). Error Bars =
SEM/(n = 5).
out of 32 kidneys) but similar long-term survival rates com-
pared to other type of donors (29). The transplant group
from The National Taiwan University Hospital, used VA per-
fusion with oxygenation (ECS) at 4◦C. They reported 66%
of immediate graft function, and 33% incidence of DGF
that resolved with short-term (1–2 weeks) hemodialysis
therapy (30–32). A group from Japan used rapid cooling
techniques to procure organs from DCD obtaining similar
results (12,20,32,33).
A transplant group in Spain has reported using normother-
mic ECMO perfusion to support the potential donor until
organ procurement (34). In 2000, Valero et al. reported sig-
nificantly lower rates of DGF (13%) and no PGNF in kidneys
from DCD when ECMO was used during organ donation
in DCD (21). Our group at the University of Michigan Hos-
pital, uses normothermic ECMO in DCD Maastricht type
II and IV donors and reported low rates of DGF (8%), no
PGNF, and an increment of the organ pool at our institution
by 33% (9,21,35).
Almost all the studies on DCD kidneys are based on 5 min
of warm ischemia after cardiac arrest. This study evaluated
the effectiveness of ECS during organ procurement after
longer periods of cardiac arrest/warm ischemia time. The
results indicate that implementation of ECS in the donor
during organ procurement can resuscitate kidneys to trans-
plantable state with immediate graft function after 30 min
of warm ischemia. The use of standard rapid recovery tech-
nique that is the most common method to procured DCD
organs effectively resuscitated renal grafts after 10 min
of warm ischemia, but not after 30 mins. ECS may be
useful in situations where prolonged ischemia is probable
including Maastricht type 1 and 2 donors (‘uncontrolled’)
and situations where local practice involves withdrawal
of support in a setting other than in the operating suite.
We used 37◦C (normothermic) perfusion in these experi-
ments because the best clinical results were achieved at
normothermia.
In this study, 90–100 min of ECS was used to perfuse the
donors because it represents our standard clinical and lab-
oratory practice (5,9). Current studies in our laboratory as-
sess the effects of longer ECS runs during the procurement
of abdominal organs. Despite the difference of warm is-
chemia (10 min and 30 min) in the two groups in which ECS
was implemented for organ recovery there were no signif-
icant differences between ECS perfusion flows between
them. Postreperfusion renal arterial flow was achieved in
all transplanted kidneys, indicating no complications dur-
ing vascular anastomosis, but normal values were only
achieved in the LVD group. Renal flow and function, as
measured by urine output, urine protein and creatinine
clearance, was adequate during the first 4 h posttransplant
after 10 min of warn ischemia with or without ECS, indicat-
ing kidneys could probably be recovered from clinical DCD
donors after 10 min of warm ischemic arrest. However,
in the groups that sustained longer cardiac arrest times
(30 min), kidney function was established only when ECS
was used during organ procurement. ECS helps in the cor-
rection of the acidosis before cold ischemia, restores ATP
levels, regulates calcium homeostasis, and removes locally
(renal) formed free radicals, in the donor and before cold
storage. It is possible that ECS plays an important role in
the preconditioning of organs before cold storage; this may
explains why ECS resuscitated kidneys after 30 min of ar-
rest/ischemia (36). This observation, suggests that ECS has
a protective role following a moderately severe ischemic
insult, and may allow organs to recover from prolonged
warm ischemia injury during donor reperfusion prior to cold
preservation/storage.
Limitations of this study are: (1) the swine model of car-
diac arrest does not exactly mimic the clinical situation. The
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Table 4: Histopathology of renal grafts
Group Histoslide Characteristics
LVD Normal capsule, glomeruli,




Mild mesengial cellularity was
observed with focal protein casts
in the tubules, no signs of ATN
were observed.
DCD 30 min Moderate mesangial cellularity in
the glomeruli was seen. High
protein casts and signs of mild
patchy ATN were found.
Intravascular microthrombi were
seen without infarcts.
model is both an asset and a limitation of this study. Cardiac
arrest by apnea in the swine is a very reproducible model
that permits evaluation of the variables in a standardized
fashion. However, many potential uncontrolled DCD sub-
jects will have a prolonged period of attempted resuscita-
tion by CPR and ventilation including many resuscitative
drugs. We acknowledge this limitation, but we argue that
the details of ECS must be characterized in the apneic ar-
rest model before adding the variables of CPR and donor
treatment; (2) The ECS cannulae used for blood inflow into
the circuit were placed into the EJV, due to the limited
size of the femoral vein in these size pigs; but we believe
that the insertion site of the cannulae did not affect the re-
sults. Also, an intrathoracic balloon was not used in these
studies, but it will be implemented in our DCD model for
further studies with the goal of isolating the brain from the
circulation; (3) Grafts function were not evaluated beyond
4 h. The swine model simulates the agonal period in ‘con-
trolled’ DCD, but is certainly less variable than observed in
clinical practice. We did not evaluate graft function beyond
4 h to avoid the problems of animal recovery and graft re-
jection. Kidneys that did not function immediately might
recover with longer time (as in DGF). Conversely, kidneys
that function immediately after transplant will function in-
definitely depending on prevention of rejection; (4) CrCl
was measured using a 4-h timed collection, not the clini-
cal standard based on a 24-h urine sample collection, but
Bloor et al., proposed that when healthy subjects with nor-
mal renal function preoperative (such as the scenario of
our study) are used a 4-h CrCl prediction method corre-
lates with CrCl measurement (37).
In a different model, we have reported that room temper-
ature perfusion is equivalent to perfusion at 37◦. We have
also reported that heparin given 5 min after arrest (with
CPR) is as effective as heparin before arrest (38). We also
evaluated if pulmonary congestion occurs during ECS with
the heart arrested and we described an in vivo method to
assess if lungs are suitable for transplantation from DCD
donors following ECS resuscitation. ECS does not cause
pulmonary congestion, and lungs retain adequate function
for transplantation, and compliance correlated with lung
function (39). Our results indicated that ECS resuscitation
of DCD kidneys is feasible and allows for assessment of
function prior to procurement by quantification of UO and
urine components in the donor. Future studies include the
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identification of the maximal cardiac arrest/warm ischemia
time in which organs from DCD can be successfully resus-
citated with ECS, as well as the optimization of the ECS
perfusion (temperature, diuretics, n-acetylcysteine, throm-
bolytic agents, etc.) with the goal to minimize the ischemic
reperfusion injury of DCD abdominal grafts, and/or the ad-
dition of leukocyte depletion filters to the ECS circuit. Fi-
nally, this model also creates the opportunity to improve
DCD–ECS organ recovery runs with the goal to increase
the ratio of functional organs per donor, including liver, lung
and pancreas donation in DCD.
Conclusions
(1) Kidneys may be successfully recovered from DCD
donors after 10 min of arrest/warm ischemia (but not after
30 min); (2) The use of normothermic venoarterial perfu-
sion of oxygenated blood (ECS) can resuscitate kidneys
to transplantable status after 30 min of warm ischemia
in a large animal model of DCD organ donation; (3) This
study adds supporting physiologic data from a large animal
model to the clinical data in human DCD donors that ECS
improves posttransplant outcomes.
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